Clinical Trial

Intra-wound Vancomycin Powder for Prevention of Surgical Site Infection Following Spinal Surgery

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated November 27, 2024 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Cefazolin is given routinely pre and intraoperatively for patients undergoing spinal surgery to reduce the rate of infection. Intra-wound admission of Vancomycin powder has been suggested to reduce wound infection rates. Therefore, this study aims to compare the rate of wound-related complications between patients receiving standard treatment compared to patients receiving an addition of topical Vancomycin and to identify the optimal Vancomycin dosage. All groups will receive the recommended regimen of routine IV antibiotic prophylaxis.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-07-23; most recent amendment 2024-11-24.
Trial Details
NCT Number NCT05959603
Lead Sponsor Rabin Medical Center
Conditions Infection
Enrollment 363 participants
Start Date 2020-05-31
Primary Completion 2025-12-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2024-11-27